Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer — NEJM
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 ...